PRODUCING PEGYLATED FRAGMENTS OF GD2-SPECIFIC ANTIBODIES INDUCING DIRECT CELL DEATH OF GD2-POSITIVE TUMOR CELLS, AND USE THEREOF IN THERAPY OF GD2-POSITIVE TUMORS Russian patent published in 2018 - IPC C07K16/30 A61K39/00 A61P35/00

Abstract RU 2663104 C1

FIELD: biotechnology.

SUBSTANCE: invention relates to biotechnology, specifically to the creation of a multivalent protein structure of a new format based on several fragments of antibodies conjugated to a polyethylene glycol molecule, and having an affinity for ganglioside GD2, which can be used in medicine. Said structure is used as an active ingredient in pharmaceutical compositions for treating many types of oncological diseases characterized by the expression of ganglioside GD2 on the surface of tumor cells, such as neuroblastoma, small-cell lung cancer, sarcoma, glioma, retinoblastoma, melanoma and others.

EFFECT: invention provides higher efficacy and safety when used in clinical practice due to multivalence and absence of undesirable effector functions compared to monoclonal antibodies against ganglioside GD2.

14 cl, 8 dwg, 2 tbl

Similar patents RU2663104C1

Title	Year	Author	Number
NOVEL PROTEIN STRUCTURES FOR DIAGNOSING AND THERAPY OF GD2-POSITIVE DISEASES	2019	Kholodenko Roman Vasilevich Doronin Igor Igorevich Rozov Fedor Nikolaevich Kholodenko Irina Viktorovna	RU2708136C1
CREATION OF CONJUGATES OF GD2-SPECIFIC ANTIBODIES AND FRAGMENTS OF GD2-SPECIFIC ANTIBODIES WITH PREPARATIONS	2019	Kholodenko Roman Vasilevich Doronin Igor Igorevich Larin Sergei Sergeevich Kibardin Aleksei Vladimirovich Rozov Fedor Nikolaevich Kholodenko Irina Viktorovna	RU2733430C1
GD2 BINDING MOLECULE	2020	Shiku, Hiroshi Akahori, Yasushi Miwa, Hiroshi Fujiwara, Hiroshi Furukawa, Koichi Furukawa, Keiko Ohmi, Yuhsuke	RU2824670C2
HIGH-AFFINITY ANTI-GD2 ANTIBODIES	2014	Cheung Naj-Kong V. Akhmed Makhiuddin Chzhao Tsi	RU2680267C2
USE OF O-ACETYLATED GD2 GANGLIOSIDE AS TARGET AS NOVEL THERAPEUTIC AND DIAGNOSTIC APPROACH IN MALIGNANT GROWTHS CONTAINING TUMOUR STEM CELLS	2014	Birkl Stefan Koshonno Deni Dorvijyu Milen Le Dussal Zhan-Mark Term Mikael	RU2702428C2
MONOCLONAL ANTIBODY OR ITS ANTIGEN-BINDING FRAGMENT WHICH SPECIFICALLY BINDS TO GD2 (GD2 GANGLIOSIDE) AND ITS USE	2021	Ageev Sergej Andreevich Chernykh Yuliya Sergeevna Kondinskaya Diana Aleksandrovna Shigina Valeriya Evgenevna Sakharova Dina Khajdarovna Grefenshtejn Mariya Anatolevna Stolyarova Alina Konstantinovna Solovev Valerij Vladimirovich Yakovlev Pavel Andreevich Morozov Dmitrij Valentinovich	RU2796937C2
ANTIBODY AGAINST GD2-O-ACETYLATED GANGLIOSIDE WITH PRO-APOPTOTIC ACTIVITY	2014	Le Dussal Zhan-Mark Term Mikael Dorvijyus Milen	RU2679715C1
USE OF MONOCLONAL ANTIBODIES SPECIFIC TO O-ACETYLATED FORM OF GANGLIOSIDE GD2 FOR TREATING CERTAIN FORMS OF CANCER	2007	Birkl' Stefan Mjussini Zhan-Mari Obri Zhak Barbe Zhak Shatal' Zhan-Fransua	RU2462476C2
GENETIC CONSTRUCT CODING STRUCTURE OF T-CELL CHIMERIC RECEPTOR BASED ON SINGLE-CHAIN VHH ANTIBODIES SPECIFIC TO TUMOUR RECEPTOR CD47 FOR THE TARGETED IMMUNOTHERAPY OF MALIGNANT GROWTHS	2017	Chumakov Stepan Petrovich Kravchenko Yuliya Evgenevna Kravchenko Dmitrij Sergeevich Frolova Elena Ivanovna	RU2707535C2
USE OF THE ANTI-O-ACETYLATED GANGLIOSIDE GD2 ANTIBODY FOR IMPROVING THE THERAPEUTIC POTENTIAL OF DRUGS	2017	Birkl, Stefan Flerans, Zhyulen Farazh, Sebastyan Le Dussal, Zhan-Mark Koshonno, Deni Term, Mikael Assulin, Brizhitt	RU2771173C2

RU 2 663 104 C1

Authors

Kholodenko Irina Viktorovna

Doronin Igor Igorevich

Kholodenko Roman Vasilevich

Dates

2018-08-01—Published

2017-07-13—Filed